Sequencing the anti-EGFR-TKIs; route to the longest survival

Sequencing the anti-EGFR-TKIs; route to the longest survival

Saved in:

Bibliographic Details
Main Authors:	H.G. Güzel, Y. İlhan, A.H. Önder
Format:	Article
Language:	English
Published:	Elsevier 2024-12-01
Series:	ESMO Real World Data and Digital Oncology
Online Access:	http://www.sciencedirect.com/science/article/pii/S2949820124000523
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Reply to the Correspondence regarding “Sequencing the anti-EGFR-TKIs; route to the longest survival” by H.G. Güzel et al.
by: Y. Uehara, et al.
Published: (2025-03-01)

Prognostic factors influencing overall survival in stage IV EGFR-mutant NSCLC patients treated with EGFR-TKIs
by: Linwu Kuang, et al.
Published: (2025-03-01)

The Effects of Silibinin Combined With EGFR‐TKIs in the Treatment of NSCLC
by: Xiaocen Wang
Published: (2025-02-01)

Revolutionizing NSCLC Treatment: Immunotherapy Strategies for EGFR‐TKIs Resistance
by: Jin Tian, et al.
Published: (2024-12-01)

Application of EGFR-TKIs in brain tumors, a breakthrough in future?
by: Shiying Feng, et al.
Published: (2025-04-01)

Central nervous system metastases of lung adenocarcinoma harboring EGFR-activating mutations: survival results from a multidisciplinary approach, including EGFR-TKIs
by: Guilherme Harada, et al.
Published: (2020-01-01)

Expert consensus on the use of third-generation EGFR-TKIs in EGFR-mutated advanced non-small cell lung cancer with various T790M mutations post-resistance to first-/second-generation EGFR-TKIs
by: Jietao Ma, et al.
Published: (2024-10-01)

Editorial: EGFR-TKIs for lung cancer treatment: development, application, and side effects
by: Qinglin Shen, et al.
Published: (2025-05-01)

Correction: Combination of betulinic acid and EGFR‑TKIs exerts synergistic anti‑tumor effects against wild‑type EGFR NSCLC by inducing autophagy‑related cell death via EGFR signaling
by: Han Wang, et al.
Published: (2025-04-01)

Combination of betulinic acid and EGFR-TKIs exerts synergistic anti-tumor effects against wild-type EGFR NSCLC by inducing autophagy-related cell death via EGFR signaling pathway
by: Han Wang, et al.
Published: (2024-05-01)

GLUT1 sensitizes tumor cells to EGFR-TKIs by binding with activated EGFR and regulating its downstream signaling pathways
by: Zhangrong Xie, et al.
Published: (2025-05-01)

Survival impact and risk factors of skeletal muscle loss during first-line EGFR-TKIs therapy in advanced lung adenocarcinoma patients
by: Xin Nie, et al.
Published: (2025-03-01)

Real-world outcomes of treatment strategy between first-line osimertinib, first/second-generation EGFR-TKIs followed by osimertinib and without osimertinib in advanced EGFR-mutant NSCLC
by: Y. Uehara, et al.
Published: (2024-09-01)

High-dose third-generation EGFR-TKIs combined with intrathecal pemetrexed in advanced EGFR-mutant NSCLC with leptomeningeal metastases following EGFR-TKI therapy
by: Shugui Wu, et al.
Published: (2025-05-01)

Profiling of driver mutations in lung adenocarcinoma patients identifies rare compound EGFR mutations sensitive to second-generation EGFR-TKIs
by: Jun Li, et al.
Published: (2024-12-01)

Real-world comparative outcomes of EGFR-TKIs for first-line treatment of EGFR+ metastatic non–small-cell lung cancer
by: Kibum Kim, et al.
Published: (2025-01-01)

Comparison of first-generation EGFR-TKIs combined with low-dose bevacizumab versus osimertinib in untreated advanced EGFR-mutated NSCLC
by: Yingqi Xu, et al.
Published: (2025-12-01)

EGFR‐TKIs Induced DPP4 Drives Metabolic Reprogramming of Persister Cells in Lung Cancer
by: Yuanzhou Zhang, et al.
Published: (2025-08-01)

Non-cancerous CT findings as predictors of survival outcome in advanced non-small cell lung cancer patients treated with first-generation EGFR-TKIs.
by: Pakorn Prakaikietikul, et al.
Published: (2025-01-01)

Longest Path Reroute to Optimize the Optical Multicast Routing in Sparse Splitting WDM Networks
by: Huanlin Liu, et al.
Published: (2015-01-01)

Letter to the Editor: EGFR-TKIs Combined with Allogeneic CD8+ NKT Cell Immunotherapy to Treat Patients with Advanced EGFR-Mutated Lung Cancer
by: Hinpetch Daungsupawong PhD, et al.
Published: (2024-10-01)

The Efficacy of Synchronous Combination of Chemotherapy and EGFR TKIs for the First-Line Treatment of NSCLC: A Systematic Analysis.
by: Han Yan, et al.
Published: (2015-01-01)

Risk factors for radiation pneumonitis in NSCLC patients treated with third-generation EGFR TKIs and chest radiotherapy
by: Nan Zhao, et al.
Published: (2025-05-01)

Research Status and Progress of Third-generation EGFR-TKIs  in Elderly Patients with Non-small Cell Lung Cancer
by: Xue CHEN, et al.
Published: (2025-05-01)

Effects of EGFR-TKIs combined with intracranial radiotherapy in EGFR-mutant non-small cell lung cancer patients with brain metastases: a retrospective multi-institutional analysis
by: Mingfeng He, et al.
Published: (2025-01-01)

An Erdős-Révész Type Law for the Length of the Longest Match of Two Coin-Tossing Sequences
by: Karl Grill
Published: (2025-01-01)

Quantitative CT variables enabling response prediction in neoadjuvant therapy with EGFR-TKIs: are they different from those in neoadjuvant concurrent chemoradiotherapy?
by: Yousun Chong, et al.
Published: (2014-01-01)

High-dose furmonertinib plus bevacizumab in EGFR-mutant non-small cell lung cancer with brain metastases after resistance to third-generation EGFR-TKIs: A retrospective study
by: Yin Pan, et al.
Published: (2025-11-01)

Concomitant Use of Analgesics and EGFR TKIs in Lung Cancer Patients: Outcomes and Perspectives From a Finnish Retrospective Register–Based Study
by: Laura S. Puuniemi, et al.
Published: (2025-07-01)

Proteomic Profiling Reveals TPR and FGA as Predictive Serum Biomarkers of Relapse to First- and Second-Generation EGFR-TKIs in Advanced Lung Adenocarcinoma
by: Pritsana Raungrut, et al.
Published: (2025-06-01)

Potential biomarkers of primary resistance to first- and second-generation EGFR-TKIs in non-small-cell lung cancer: a real-world study
by: Jingyi Wang, et al.
Published: (2025-04-01)

Transitional CXCL14+ cancer‐associated fibroblasts enhance tumour metastasis and confer resistance to EGFR‐TKIs, revealing therapeutic vulnerability to filgotinib in lung adenocarcinoma
by: Weijiao Xu, et al.
Published: (2025-04-01)

Estimation of Longest Stability Interval for a Kind of Explicit Linear Multistep Methods
by: Y. Xu, et al.
Published: (2010-01-01)

Anti-EGFR aptamer exhibits direct anti-cancer effects in NSCLC cells harboring EGFR L858R mutations
by: Brian J. Thomas, et al.
Published: (2024-11-01)

CHANGING IMAGE OF TKIS: ORIGINAL, BIOSIMILAR AND GENERIC OPTIONS
by: Cenk Sunu
Published: (2024-12-01)

Microbial genomic database of the Yangtze River, the third-longest river on Earth
by: Minglei Ren, et al.
Published: (2025-07-01)

Sex-specific differences in performance and pacing in the world’s longest triathlon in history
by: Beat Knechtle, et al.
Published: (2025-08-01)

On the Convergence Rate for the Longest at Most <i>T</i>-Contaminated Runs of Heads
by: István Fazekas, et al.
Published: (2025-01-01)

Femoral bone metastasis is a poor prognostic factor in EGFR-TKIs-treated patients with -mutated non-small-cell lung cancer: a retrospective, multicenter cohort study
by: Ichidai Tanaka, et al.
Published: (2024-12-01)

Combination therapy of TKIs and ICIs for the treatment of anaplastic thyroid carcinoma
by: Xi Zhang, et al.
Published: (2025-05-01)